Streetbeat News

Analyst Ratings

ACAD

ACADIA Pharmaceuticals (NASDAQ:ACAD) has received various analyst ratings in the last quarter, with a total of 20 analysts giving an average price target of $28.43, which is lower than the current price of $29.2. This average price target has increased by 16.37% from the previous average of $24.43.

Portfolio Pulse from Benzinga Insights

August 04, 2023 | 1:06 pm

NRDS

Oppenheimer analyst Jed Kelly has maintained an Outperform rating on Nerdwallet (NASDAQ:NRDS) but lowered the price target from $17 to $16.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 1:06 pm

JCI

Oppenheimer analyst Noah Kaye has maintained an 'Outperform' rating on Johnson Controls Intl (NYSE:JCI) but lowered the price target from $79 to $78.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 1:06 pm

BOOT

Citigroup analyst Steven Zaccone maintains a Buy rating on Boot Barn Holdings (NYSE:BOOT) and raises the price target from $106 to $116.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 1:06 pm

RELY

Citigroup analyst Andrew Schmidt maintains a Buy rating on Remitly Global (NASDAQ:RELY) and raises the price target from $23 to $25.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 1:05 pm

DASH

Oppenheimer analyst Jason Helfstein maintains an Outperform rating on DoorDash (NYSE:DASH) and raises the price target from $85 to $110.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 1:05 pm

ETSY

Oppenheimer analyst Jason Helfstein maintains an Outperform rating on Etsy (NASDAQ:ETSY) but lowers the price target from $150 to $135.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 1:05 pm

CTSH

Citigroup analyst Ashwin Shirvaikar maintains a Neutral rating on Cognizant Tech Solns (NASDAQ:CTSH) and raises the price target from $65 to $72.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 1:05 pm

EDIT

Oppenheimer analyst Jay Olson has reiterated a 'Perform' rating on Editas Medicine (NASDAQ:EDIT) and maintained a $12 price target.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 1:05 pm

GNRC

Oppenheimer analyst Christopher Glynn maintains an 'Outperform' rating on Generac Hldgs (NYSE:GNRC) but has lowered the price target from $145 to $130.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 1:04 pm